Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

COALIZAO ACTION
  NCT04394377		 RCTanticoagulant, curative dosecontrolCOVID 19 hospitalizedsome concern
311/304 inconclusive

    COVID-19 mild to moderate meta-analysis

    ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients)
          NCT02735707    		 RCTanticoagulant, curative dosecontrolCOVID-19 mild to moderatesome concern
    		1190/1054 conclusif
    • demonstrated 27 % increase in clinical improvement (28-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
    atypical endpoints without correspondence with those of the others trials

    COVID-19 severe or critically meta-analysis

    REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients)
          NCT02735707    		 RCTanticoagulant, curative dosecontrolCOVID-19 severe or criticallysome concern
    		591/616 inconclusive
    • inconclusive 17 % decrease in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
    1 study excluded by filtering options (0 RCT / 1 OBS)

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

     

    - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons